{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Talleur AC"],"funding":["NCI NIH HHS"],"pagination":["5737-5749"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9647829"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6(21)"],"pubmed_abstract":["T cells expressing CD19-specific chimeric antigen receptors (CD19-CARs) have potent antileukemia activity in pediatric and adult patients with relapsed and/or refractory B-cell acute lymphoblastic leukemia (B-ALL). However, not all patients achieve a complete response (CR), and a significant percentage relapse after CD19-CAR T-cell therapy due to T-cell intrinsic and/or extrinsic mechanisms. Thus, there is a need to evaluate new CD19-CAR T-cell products in patients to improve efficacy. We developed a phase 1/2 clinical study to evaluate an institutional autologous CD19-CAR T-cell product in pediatric patients with relapsed/refractory B-ALL. Here we report the outcome of the phase 1 study participants (n = 12). Treatment was well tolerated, with a low incidence of both cytokine release synd"],"journal":["Blood advances"],"pubmed_title":["Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL."],"pmcid":["PMC9647829"],"funding_grant_id":["P30 CA021765","R01 CA237311"],"pubmed_authors":["Metais JY","Madden R","Inaba H","Lockey T","Pui CH","Hurley C","Suliman A","Triplett BM","Sharma A","Qudeimat A","Patil SL","Bragg A","Crawford JC","Akel S","Willis C","Tuggle-Brown M","Langfitt D","Youngblood B","Cheng C","Schell S","Obeng EA","Talleur AC","Geiger TL","Gottschalk S","Srinivasan A","Zheng W","Mamcarz E","Meagher MM","Huang S","Li Y","Karol SE","Zebley C","Cullins D","Velasquez MP","Zhou SM","Thomas PG"],"additional_accession":[]},"is_claimable":false,"name":"Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL.","description":"T cells expressing CD19-specific chimeric antigen receptors (CD19-CARs) have potent antileukemia activity in pediatric and adult patients with relapsed and/or refractory B-cell acute lymphoblastic leukemia (B-ALL). However, not all patients achieve a complete response (CR), and a significant percentage relapse after CD19-CAR T-cell therapy due to T-cell intrinsic and/or extrinsic mechanisms. Thus, there is a need to evaluate new CD19-CAR T-cell products in patients to improve efficacy. We developed a phase 1/2 clinical study to evaluate an institutional autologous CD19-CAR T-cell product in pediatric patients with relapsed/refractory B-ALL. Here we report the outcome of the phase 1 study participants (n = 12). Treatment was well tolerated, with a low incidence of both cytokine release synd","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2026-05-31T23:09:57.562Z","creation":"2024-11-20T15:24:29.929Z"},"accession":"S-EPMC9647829","cross_references":{"pubmed":["35446934"],"doi":["10.1182/bloodadvances.2021006293"]}}